Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 47, Issue 22, pp. 5846-5852
PubMed
Published By
Print ISSN
Online ISSN
History
- Received June 10, 1986
- Revision received April 13, 1987
- Revision received July 17, 1987
- Accepted July 28, 1987
- Published first November 1, 1987.
Copyright & Usage
©1987 American Association for Cancer Research.
Author Information
- Malcolm F. G. Stevens,
- John A. Hickman,
- Simon P. Langdon2,
- David Chubb,
- Lisa Vickers,
- Robert Stone2,
- Ghousia Baig,
- Colin Goddard2,
- Neil W. Gibson2,
- John A. Slack,
- Christopher Newton,
- Edward Lunt,
- Christian Fizames, and
- François Lavelle
- Cancer Research Campaign Experimental Chemotherapy Group, Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, United Kingdom [M. F. G. S., J. A. H., D. C., S. P. L., L. V., R. S., G. B., C. G. N. W. G., J. A. S.]; May and Baker Ltd., Dagenham, Essex RM10 7XS, United Kingdom [C. N., E. L.]; and Rhone-Poulenc Santé, Centre de Recherches de Vitry, 94407, Vitry Sur Seine, Cedex, France [C. F., F. L.]
November 1987
Volume 47, Issue 22
Volume 47, Issue 22
Antitumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine
Jump to section
Advertisement